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erythrocytosis caused by hypoxia present in advanced cases of COPD. However, it was shown in
several studies that some COPD patients had anemia rather than erythrocytosis
Aim: The aim of this work was to assess the changes in erythropoietin in COPD patients during
exacerbation and after remission.
Subjects and methods: This work was done on 50 subjects, Group 1:40 COPD patients plus
Group I 1: 10 age matched apparently healthy control subjects. For all history taking, full clinical
exam, PFTs (spirometry), EPO hormone measurement on human serum by ELIZA (EPO hormone
was measured during exacerbation and after remission), oxygen saturation and routine labs (CBC,
Liver and Renal function) were performed.
Results: Level of erythropoietin hormone was significantly higher in COPD patients with mean
(21.92 ± 6.64 mU/ml) than control with mean (9.42 ± 1.5 mU/ml) and higher during remission
(24.21 ± 6.58 mU/ml) than during exacerbation (21.92 ± 6.64 mU/ml), also was significantly
higher during remission in grade (II, III) (25.68 ± 2.57, 33.71 ± 2.16 mU/ml) than grade (I, IV)
(16.04 ± 0.89, 19.39 ± 1.28 mU/ml) COPD patients respectively. Erythropoietin hormone level
was significantly higher in anemic than non anemic COPD patients. It was (27.94 ± 6.33 mU/
ml) (20.84 ± 4.83 mU/ml) respectively, and it was significantly inversely related to oxygen satura-
tion & both of HB and Hct in COPD patients.
Conclusion: EPO hormone level was significantly higher in grade (II, III) than grade
(I, IV) COPD patients (p= 0.005), and also COPD with anemia was higher in stage (II, III)
than stage (I, IV), EPO hormone level significantly higher in anemic than non anemic COPDrbation
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nd/4.0/).Table 1 Demograghic data of studied group.
Case group Control group
Sex n&%
Male 33 (82.5%) 5 (50%)
Female 7 (17.5%) 5 (50%)
Age in years
Range 47–61 46–61
Mean ± SD 54.88 ± 7.48 53.0 ± 6.57
FVC %
Range 30–71 47–75
Mean ± SD 48.2 ± 11.94 61.1 ± 14.18
FEV1 %
Range 17–81 47–79
Mean ± SD 39.9 ± 18.17 63.7 ± 16.84
FEV1/FVC %
Range 26–69 80–101
Mean ± SD 54.25 ± 12.83 90.5 ± 10.75Introduction
COPD is a common preventable and treatable disease, charac-
terized by persistent air flow limitation that is usually progres-
sive and associated with an enhanced chronic inflammatory
response in the airways and the lung to noxious particles or
gases. Exacerbations and comorbidities contribute to the over-
all severity in individual patients [1]. Acute exacerbation of
chronic obstructive pulmonary disease is defined as acute event
characterized by a worsening of the patient’s respiratory symp-
toms that is beyond normal day to day variations and leads to
a change in medications [1]. Erythropoietin is an endogenous
glycoprotein hormone that controls erythropoiesis, or red
blood cell production. It is a cytokine (protein signaling mole-
cule) for erythrocyte (red blood cell) precursors in the bone
marrow. Human EPO has a molecular weight of 34 kDaalso
called hematopoietin or hemopoietin [2]. Diminished arterial
oxygen content associated with anemia or hypoxia is the major
stimulus for EPO production and usually produces an expo-
nential increase [3]. It has long been known that COPD causes
polycythemia secondary to erythrocytosis caused by hypoxia
present in advanced cases of COPD [4]. However, it was shown
in several studies that some COPD patients had anemia rather
than erythrocytosis [5].
Aim of the work
This work was carried out to assess the changes in erythropoi-
etin in COPD patients during exacerbation and after
remission.
Subjects and methods
This study was performed in Banha University Hospitals
Chest Departmenton 50 subjects during December 2014 and
December 2015. They were divided into 2 groups: Group 1:
40 patients with COPD, Erythropoietin (EPO) hormone will
be measured during exacerbation and after remission. Group
2: 10 apparently healthy subjects.
Inclusion criteria
Patients with COPD diagnosed according to GOLD [1]
criteria.
Exclusion criteria
Patients with history of bronchial asthma., malignancy,
haematologic disorder, systematic or autoimmune disorder,
thyroid disease, liver cirrhosis, heart failure, gastrointestinal
or other hemorrhage, renal failure and history of blood trans-
fusion in the last 4 months were included.zzar et al., Evaluation of erythropoietin
berc. (2016), http://dx.doi.org/10.1016/All subjects were submitted to the following:
(1) History taking:History of smoking, chest symptoms and
any other co-morbidities.
(2) Clinical examination: Both general and local
examination.
(3) Radiological examination: Plain chest X ray postero-
anterior and left lateral views.
(4) Pulmonary function tests (spirometry) before and after
bronchodilatation.
(5) Routine investigations as: Electrocardiography, complete
blood count, liver function tests, kidney function tests
and blood sugar testing.
(6) Measuring the oxygen saturation in the blood by pulse
oximetry.
(7) Erythropoietin hormone measurement:
–The determination of EPO should be performed on
human serum by ELISA.
Three cm of whole blood without adding any anticoagulant
was collected in the morning between 7:30 a.m. to 12:00 noon,
because diurnal variation of erythropoietin has been reported
[6]. Allow blood to clot between 2 and 8 C. Then, the serum
should be promptly separated, preferably in a refrigerated cen-
trifuge, and stored at 15 C or lower. Serum samples frozen
at 15 C are stable for up to 12 month.
–Range of EPO in healthy individuals: (0–19) mU/ml (milli-
units per milliliter [7].
Results
Table 1 shows that: (82.5%) were males and (17.5%) were
females COPD patients. The mean age for patients washormone in chronic obstructive pulmonary disease patients during exacerbation
j.ejcdt.2016.08.015
Table 2 Comparison of erythropoietin, oxygen saturation and hemoglobin between case and control groups.
Case group (mean ± SD) Control group (mean ± SD) St t test p value
Sex n&%
Male 33(82.5%) 5(50%) 3.02
Female 7(17.5%) 5(50%)
Age in years 54.88 ± 7.48 53.0 ± 6.57 0.725 >0.05
HBgm/dl 11.96 ± 1.69 13.25 ± 0.63 2.35 <0.05
O2 saturation % 89.63 ± 2.88 97.4 ± 0.52 8.44 <0.005
EPO mU/ml 21.92 ± 6.64 9.42 ± 1.5 5.87 <0.005
Figure 1 Comparison of erythropoietin, oxygen saturation and
hemoglobin between case and control groups.
Evaluation of erythropoietin hormone in chronic obstructive pulmonary disease patients 354.88 ± 7.48 years and for control was 53.0 ± 6.57. FEV1%
and FVC% were significantly higher in control group than
in case group.
Table 2 and Fig. 1 show that hemoglobin and Oxygen sat-
uration were significantly lower in cases than in control
groups, and EPO level was significantly higher in cases than
in control groups.
Table 3 and Fig. 2 show that EPO hormone level was sig-
nificantly higher in grade (II, III) than grade (I, IV) COPD
patients and that it is higher during remission than during
exacerbation of COPD.
Table 4 shows that COPD with anemia was higher in stage
(II,III) than stage (I,IV). EPO hormone level was significantlyTable 3 Comparison of erythropoietin hormone level in COPD pa
Grades Grade I Grade II
EPO mU/ml during acute exacerbation 13.91 ± 0.65 23.49 ±
EPO mU/ml during remission 16.04 ± 0.89 25.68 ±
Table 4 Comparison between EPO hormone and COPD grading in
Case group with anemia (19) mean ± SD
EPO mU/ml AE 25.64 ± 6.28
EPO mU/ml R 27.94 ± 6.33
Grade n & %
Stage I: Mild 0(0.0)
Stage II: Moderate 7(36.8%)
Stage III Severe 8(42.1%)
Stage IV: Very severe 4(21.1%)
Please cite this article in press as: A.G. El Gazzar et al., Evaluation of erythropoietin
and after remission, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/higher in anemic than non anemic COPD patients during
remission and exacerbation
Table 5 shows that EPO hormone level was significantly
higher during remission than during exacerbation and Oxygen
saturation was significantly higher during remission than dur-
ing exacerbation.
Table 6 and Fig. 3 show a significant negative correlation
between EPO hormone level and both HB & Hct level in
COPD patients.
Table 7 shows a significant negative correlation between
EPO hormone level and Oxygen saturation during exacerba-
tion and remission in COPD patients.
Discussion
The study was aiming at assessment of erythropoietin changes
in different stages of COPD as COPD is traditionally associ-
ated with polycythemia (5) also the assumption that anemia
frequently occurs in patients with COPD (8). This study was
conducted on 50 subjects, 40 COPD patients 33 males
(82.5%) and 7 females (17.5%) (EPO hormone will be mea-
sured during exacerbation and after remission) their age rang-
ing from 47 to 61 years plus 10 age matched apparently healthy
control group 5 males (50%) and 5 females (50%) their age
ranging from (46 to 61) years and that both FEV1%, FVC
% were significantly higher in the control group than in the
case group (Table 1).
In the current study, the level of EPO hormone was found
to be higher in COPD patients with mean (21.92 ± 6.64 mU/
ml) compared to controls with mean (9.42 ± 1.5 mU/ml)tients gradings.
Grade III Grade IV F test p value
2.6 31.53 ± 1.98 16.94 ± 1.23 159.74 <0.005
2.57 33.71 ± 2.16 19.39 ± 1.28 145.6 <0.005
COPD patients with and without anemia.
Case group without anemia (21) mean ± SD St test p value
18.55 ± 5.05 3.95 <0.005
20.84 ± 4.83 4.01 <0.005
4(19.0%)
3(14.3%) 12.58 <0.005
2(9.5%)
12(57.1%)
hormone in chronic obstructive pulmonary disease patients during exacerbation
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Table 5 Comparison of O2 saturation and EPO during exacerbation and after remission in COPD patients.
Among cases (40) During exacerbation (mean ± SD) After remission (mean ± SD) Paired t test p value
O2 saturation % 89.63 ± 2.88 92.53±.24 12.38 <0.005
EPO mU/ml 21.92 ± 6.64 24.21 ± 6.58 16.13 <0.005
Table 6 Correlation between EPO hormone level and both
Hemoglobin and Hct levels in groups of COPD patients.
Among COPD patients EPO
R p
HBgm/dl 0.492 <0.005
Hct % 0.516 <0.005
Figure 2 Comparison of Erythropoietin hormone level in COPD
patients gradings.
4 A.G. El Gazzar et al.and the difference between them was statistically highly signif-
icant (p< 0.005) (Table 2 and Fig. 1).
In the current study, the concentration of hemoglobin was
lower in COPD cases with mean (11.96 ± 1.69 g/dl) compared
to controls hemoglobin mean (13.25 ± 0.63 g/dl) and the dif-
ference between them was statistically significant (p< 0.05)
(Table 2 and Fig. 1).
Oxygen saturation in COPD patients was lower than con-
trols and its mean in COPD patients was (89.63 ± 2.88%)
while for control was (97.4 ± 0.52%) and the difference
between them was statistically highly significant (p< 0.005)
(Table 2 and Fig. 1).
These results agree with [9]who measured the level of hemo-
globin, hematocrit, oxygen saturation in blood and erythropoi-
etin hormone in (41) patients with COPD and ten healthy age
and sex matched control subjects and the results showed that
mean hemoglobin for COPD cases was (13.82 ± 1.95 g/dL)
while for the control it was (14 ± 1.27 g/dl) with no statistical
significance. Mean value of Hematocrit was (42.1 ± 6.09%)
for COPD and (43.8 ± 3.19%) for control and result was
not statistically significant. However oxygenation parameters
in ABGs showed statistically significant differences between
the COPD patients and the control group SaO2 was (84.9
± 14.7) and (96.80 ± 1.40) for COPD cases and control
respectively.
The results of this study also were in agreement with [5]
who found that EPO serum level was higher in COPD patientsPlease cite this article in press as: A.G. El Gazzar et al., Evaluation of erythropoietin
and after remission, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/than in control groups. In the current study, COPD patients
were divided into 4 stages according to (1) and erythropoietin
was correlated to degree of severity of COPD in (Tables 3 and
4 and Fig. 2), the results found that EPO hormone level was
higher during remission than exacerbation of COPD patients
and difference was statistically highly significant (p< 0.005).
It was found that EPO hormone levels during remission were
low in stage I disease (16.04 ± 0.89 mU/ml), increased in stage
II (25.68 ± 2.57 mU/ml), while maximally increased in stage
III (33.71 ± 2.16 mU/ml) and then decreased in stage IV
(19.39 ± 1.28 mU/ml). On reflecting these changes on the rou-
tinely measured parameters of complete blood picture, the per-
centage of anemia in stage I disease was (0%) and increased to
(36.8%) in stage II, reaching (42.1%) in stage III dropping
again to (21.1%) in stage IV.
These results are in agreement with [9] who found that the
erythropoietin hormone level was (15.24 ± 2.6 mU/ml) in
stage I disease, (22.61 ± 5.68 mU/ml) in stage II, (33.59
± 4 mU/ml) in stage III, then decrease to (17.9 ± 3.3 mU/
ml) in stage IV. Also the total percentage of anemia in COPD
patients was (46.3%), in comparison to (51.3%) non anemic
and (2.4%) polycythemic. The percentage of anemia was
(27.3%) in stage I disease, followed by (38.0%) in stage II,
raised to (100%) in stage III then dropped to (58.33%) in stage
IV.
COPD itself may cause anemia as achronic disease, short-
ened survival of RBCS as a result of raised level of inflamma-
tory mediators as IL1, IL6, CRP and TNF [8]. This might
occur through shortened RBC survival, iron homeostasis dys-
regulation and impaired bone marrow erythropoietic response
[10]. Nutritional derangements in COPD patients were pro-
posed as a cause for anemia [11]. Also, tobacco smoking and
its role in oxidative stress has a role in RBCs production
[12]. Lastly, the role of comorbidities frequently encountered
in COPD patients as upper GI bleeding and folate deficiency
was proposed however they were largely related to smoking
also [5]. This finding is common in COPD and exaggerated
during exacerbation.
Contrary to this study result [5], was performed in Iran, on
Eighty patients. Hemoglobin and erythropoietin levels were
assessed in all patients. The results showed that anemia of
chronic disease was present in (13) of 80 patients (16%). The
mean serum levels of EPO were 59 ± 203 (SD) l/l and 70.3
± 255 (SD) l/l in anemic and non anemic COPD patients
respectively. There was an increase in EPO hormone level in
non anemic COPD patients than anemic and this can be
explained by apart from EPO resistance, other factors may
also contribute to the lower hemoglobin level in COPD
patients. Defective EPO production and impaired iron utiliza-
tion due to factors other than inflammation can be responsible
for anemia in COPD patients as malnutrition, tobacco smok-
ing (because of its associated oxidative stress) and finally oxy-
gen therapy can theoritically blunt hypoxia-driven
erythropoiesis in COPD patients.hormone in chronic obstructive pulmonary disease patients during exacerbation
j.ejcdt.2016.08.015
Figure 3 Correlation between EPO hormone level and both
Hemoglobin and Hct levels in groups of COPD patients.
Table 7 Correlation between EPO hormone level and oxygen
saturation during exacerbation and remission in COPD
patients.
Among COPD patients EPO (acute
exacerbation)
R p
O2 saturation % during acute exacerbation 0.352 <0.005
Among COPD patients EPO (remission)
R p
O2 saturation % during Remission 0.563 <0.005
Evaluation of erythropoietin hormone in chronic obstructive pulmonary disease patients 5In the current study we found that there were statistically
highly significant increases (p< 0.005) in EPO hormone level
and oxygen saturation during remission than exacerbation
(Table 5).
In agreement with this study result [13], who found that
Log-Epo plasma levels were significantly lower (0.46
± 0.32 mU/ml) in AECOPD than in stable COPD (1.05
± 0.23 mU/ml), smokers (0.95 ± 0.11 mU/ml) and never
smokers with normal lung function (0.92 ± 0.19 mU/ml)
(p< 0.01 each). Log-Epo increased from (0.49 ± 0.42 mU/
ml) during AECOPD to (0.97 ± 0.19 mU/ml) during stability
(p< 0.01) which means that the plasma levels of Epo are
reduced during ECOPD likely in relation to a burst of systemic
inflammation.
This Epo down-regulation during ECOPD can be explained
by the burst of inflammation that occurs during these clinicalPlease cite this article in press as: A.G. El Gazzar et al., Evaluation of erythropoietin
and after remission, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/circumstances, as shown here by a significant increase in leuko-
cyte and neutrophil counts, as well as by the raised concentra-
tion of hsC-RP during ECOPD. Several pieces of evidence
support this proposal. First, in vitro experiments have demon-
strated that IL-1 and TNF-suppress Epo expression and secre-
tion by activating the transcription factors GATA-2 and NF-b
[14]. Second, clinical investigations indicate that TNF-
suppresses Epo secretion in patients with advanced solid
tumors and chronic infection [15]. Third, Epo plasma levels
in anemic patients who suffer concomitantly of other inflam-
matory process are often lower than expected in relation to
their hemoglobin concentration [16]. Fourth and finally, a sig-
nificant negative association between Epo plasma levels and
both hsC-RP and neutrophils in the patients studied here.
Interestingly, this inflammatory mechanism appears to over-
come the regulation of EPO by oxygen, given that the hypox-
emia that occurs during exacerbations of COPD would be a
strong stimulus for Epo production [17].
Contrary to this study result [8], who found that EPO level
in COPD was similar to that seen in control subjects, except in
those patients with chronic respiratory failure, severe noctur-
nal desaturation or anemia in whom EPO levels were
increased.
In the current study, there was a significant negative corre-
lation between EPO hormone level and both Hemoglobin and
Hct levels in COPD patients (Table 6 and Fig. 3).
These results are in agreement with [8] and [9] they found
that all anemic COPD patients showed elevated erythropoietin
levels. There was a significant inverse correlation between ery-
thropoietin hormone level and hemoglobin concentration
Also [13] and [18] found the same result in their studies.
In the current study there was a significant negative corre-
lation between EPO hormone and Oxygen saturation during
exacerbation and remission. (Table 7).
In agreement with the current study[9], who found that
there was a statistically significant correlation for erythropoi-
etin with age, PaO2 and SaO2 in COPD patients, as he mea-
sured the level of EPO hormone in (41) patients with COPD
and ten healthy age and sex matched control subjects, the
results showed negative correlation between EPO hormone
level and PaO2 (p= 0.85) statistically significant, and negative
correlation between EPO hormone level and SaO2 (p= 0.99).
This can be explained by diminished arterial oxygen con-
tent associated with anemia or hypoxia is the major stimulus
for EPO production and usually produces an exponential
increase. As the PaO2 of the plasma, and function of the hema-
tocrit decreases, EPO hormone concentration will increase
[19].
In agreement with this study also [20], investigated the early
changes in erythropoietin (EPO) formation in humans in
response to hypoxia. EPO levels during hypoxia were signifi-
cantly elevated.
Conclusions
EPO hormone level was significantly higher in COPD patients
than in control groups. It was significantly higher in grade (II,
III) than grade (I, IV) COPD patients, and during remission
than during exacerbation of COPD. Anemia is more in COPD
patient group than in the control group, COPD with anemia
was higher in stage (II, III) than in stage (I, IV). EPO hormonehormone in chronic obstructive pulmonary disease patients during exacerbation
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6 A.G. El Gazzar et al.level was significantly higher in anemic than non anemic
COPD patients. There is a significant negative correlation
between EPO hormone level and Oxygen saturation and both
HB & Hct levels in COPD patients.
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